Trovagene Precision Cancer Monitoring (PCM) provides noninvasive and quantitative alternatives to biopsy and imaging for tracking specific oncogene mutations over time, with the flexibility of urine- and blood-based testing.
We recently had a chance to interview one of the speakers at GTCbio’s upcoming Molecular Diagnostics Summit 2015. Dr. Mark Erlander, Chief Science Officer of Trovagene, will be giving a presentation entitled “Quantitating ctDNA Mutations from Patient Urine as an Early Pharmacodynamic Biomarker for Response to Targeted Therapy”. We caught up with him recently to ask about the liquid biopsy market and how next generation sequencing is making an impact. Read More.
Validating the potential of liquid biopsies as a viable alternative to traditional screening methods for cancer, FierceDiagnostics selects Trovagene as one of five companies to watch in the space. Read More.
Next-generation sequencing has enabled advances in oncology, both in research and clinical settings, and now seeks acceptance for a wider range of applications. At the 2015 Personalized Medicine World Conference, Genetic Engineering News took a look at some of these applications. Trovagene’s CSO, Mark Erlander, provided perspective into the potential for the growth of the liquid biopsy space. Read More.
Liquid biopsies have shown great promise in detecting and monitoring cancer. One contender, Trovagene, tells Clinica why it believes it has the edge over other companies in the space. Read More.